AlphAIAlphAI — Financial news for AI agents
simplywall.stSEP 133 min read$AMGN

Is Amgen (AMGN) Fully Valued As New IMDELLTRA Data Reshapes The Story?

Amgen (AMGN) reported Phase 3 data for IMDELLTRA combined with AstraZeneca’s Imfinzi, showing improved survival rates in small cell lung cancer. The stock has seen mixed returns recently, with a 13.70% drop over 7 days but a 40.32% gain over 1 year. Analysts debate its valuation, with fair value estimates ranging from $359.98 to $669.81, highlighting risks and growth potential.

Original reporting
simplywall.st
Published Sep 13, 2026, 4:34 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 13, 2026, 5:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$AMGN
Bullish
high confidence
Mentioned
$AMGN
Relevance
8/10
AlphAI data visualization · based on simplywall.st
Decision brief

The 30-second read

$AMGNBullishMed
01

Why it matters

The trial results provide a fresh catalyst that could narrow the valuation gap, but structural challenges may limit upside.

02

Market read

First‑report of pivotal oncology trial data for a major US biotech, likely to influence stock price and sector sentiment.

03

What to watch

Regulatory CNPV program uncertainty and manufacturing capacity constraints.

Relevance 8/10Novelty 8/10Timing: recent trial data release

Background

The article evaluates Amgen's valuation after new trial data, comparing fair‑value estimates and discussing macro‑level obesity market trends.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen reported Phase 3 DeLLphi-305 trial results for IMDELLTRA combined with AstraZeneca's Imfinzi, showing improved overall and progression‑free survival.

Expected impact

Potential upside of 5‑10% over the next week if market digests the data.

Evidence & confidence

First disclosure of pivotal Phase 3 results for a late‑stage lung‑cancer therapy, a material catalyst for a large‑cap biotech.

Market effects

Sector

May boost confidence in oncology pipelines and affect peers like Lilly and Novo Nordisk.

Regional

Positive for US biotech sector and related exchange‑traded funds.

Global

Highlights competitive dynamics in global lung‑cancer treatment market.

Counterpoint

What could challenge this read

Valuation remains stretched; legacy product erosion could offset trial upside.

Key entities

  • company
    Amgen

    US‑listed biotech firm (AMGN) reporting Phase 3 data.

  • company
    AstraZeneca

    Partner in the IMDELLTRA/Imfinzi combination trial.

Read at source← All news

Related articles

SEP 11
$AMGNHighAI 8/10

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Amgen (AMGN) and Revolution Medicines (RVMD) present contrasting investment profiles. Amgen, with $36.7B revenue and $7.7B net income in 2025, offers steady cash flows and a 2.60% dividend. Revolution Medicines, a clinical-stage biotech, has no revenue but reported a $1.1B net loss. Revolution recently gained FDA approval for Daraxonrasib, a potential breakthrough in pancreatic cancer treatment.

fool.com3 min
SEP 11
$AMGNHighAI 9/10

Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca

Amgen (AMGN) and AstraZeneca (AZN) reported positive late-stage trial results for their combination therapy, Imdelltra and Imfinzi, in extensive-stage small-cell lung cancer. The treatment improved overall survival, progression-free survival, and response rates. Imdelltra generated $513M in sales last year, and the results could expand its use. Amgen's Q2 2026 revenue rose 10%, while AstraZeneca faces investor pressure from recent setbacks.

yahoo.com2 min
SEP 10
$VRTXMed

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

Myriad Genetics (MYGN) reported Q2 revenues of $190.7M, down 10.5% YoY, missing estimates. Its stock fell 40.7% to $3.19. Halozyme Therapeutics (HALO) reported $481M in revenues, up 47.7% YoY, beating estimates. Its stock rose 24.5% to $106.74. Amgen (AMGN) reported $10.05B in revenues, up 9.5% YoY, exceeding expectations. Its stock is flat at $391.29. The market has seen shifts in leadership due to AI and geopolitical concerns.

finance.yahoo.com3 min
SEP 10
$AMGNMed

Why is Amgen stock sliding today?

Amgen (AMGN) stock fell 2.2% to $382.67 after HSBC downgraded it to Hold, cutting its price target to $425. The downgrade follows a competitor's clinical trial failure, which impacted Amgen's pipeline prospects. Analysts cited patent expirations and delayed pipeline benefits as concerns, though some reaffirmed Buy ratings due to positive trial data for Imdelltra.

investing.com2 min
SEP 10
$AMGNMedAI 8/10

AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study

Amgen (AMGN) and AstraZeneca (AZN) reported positive phase III study results for their lung cancer drug combination, Imdelltra and Imfinzi, showing improved overall and progression-free survival. The study, DeLLphi-305, evaluated the combination against Imfinzi alone in extensive-stage small-cell lung cancer (SCLC) patients. Both companies highlighted the potential market opportunity, with SCLC accounting for 15% of lung cancers and an estimated 195,000 global cases in 2026. Imdelltra's sales re

theglobeandmail.com2 min